Stryker‘s (NYSE:SYK) Homedica is on the hook for approximately $13.3 million in attorney’s fees and $513,258 in costs due to Zimmer Biomet (NYSE:ZBH) as a result of a patent dispute, according to recently unsealed court documents.
The award is the result of a long-running patent spat over polymers between the two companies that ended in four of Howmedica’s patents being invalidated, court documents indicate.
The fees were awarded on April 20, and unsealed earlier this month.
Last June, the New Jersey Supreme Court approved a bid to consolidate state court lawsuits against Stryker over an allegedly defective hip replacement device.
The company faced a number of lawsuits regarding its Lfit cobalt-chromium v40 femoral heads, including that the product corrodes when connected to a component part, which can necessitate corrective surgery.